Atlas Trials

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Clinical trial NCT06160206 · RECRUITING

Trial details

NCT number
NCT06160206
Sponsor
Academic and Community Cancer Research United
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent GlioblastomaRecurrent WHO Grade 4 Glioma
Start date
2024-10-02
Primary completion
2026-11-30
Enrollment
134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.